T gene expression involves shared and distinct DNA regulatory elements, such as recognition sites for the binding of activator protein-1 (AP-I), nuclear factor-KB (NF-KB), nuclear factor activated T cells (NFAT), and other transcription factors.'.' The tissue-specific and mitogen-inducible transcription of cytokine genes like granulocyte-macrophage colony-stimulating factor (GM-CSF) can be dictated by many mechanisms, including the presence of tissue specific transcription factors or the activation-dependent ability of these factors to bind regulatory DNA elements and activate or repress transcription. GM-CSF is expressed by activated, but not resting T cells, and plays an important role in stimulating hematopoiesis and modulating host The GM-CSF 5' flanking sequences contain a variety of transcriptional regulatory elements including an NF-KB motif,5 a CD28 response a GC-rich element, 8 an AMLl binding site: and the repeated sequence CATT(A/T). Two copies of the CATT(A/T) motif are located between base pair (bp) -57 to -24, in a region that binds nuclear proteins in DNase I footprinting assays." These sequences are required for GM-CSF promoter activity in T cells," myeloid cells," and fibroblasts,I3 and mutations in either copy of the ets family of transcription factors, is located just 3' of these CAlT(A/T) repeats, and mutagenesis of the CCT sequence abolishes (1) the constitutive (and mitogen inducible) enhancer activity of the 19-bp GM-CSF sequences, (2) the responsiveness t o transactivation by ets-1, and (3) the ability t o specifically bind ets-1 and elf-I in electrophoretic mobility shift assays (EMSA). We demonstrate that although T cells contain nuclear proteins capable of independently recognizing the ets binding site and the CATT(A/T) repeats in EMSAs, both of these regulatory elements are required for enhancer function. The strong constitutive activity of this 19-bp region suggests that negative regulation of the GM-CSF promoter is critical for the restricted expression pattern of GM-CSF mRNA. 0 1996 by The American Society of Hematology.
CATT(A/T) motif eliminates basal and inducible promoter activity.".'2 Similar sequences are found in the 5' flanking sequences of the murine and human interleukin-5 (IL-5) genes,14 and they have recently been shown to regulate IL-5 promoter activity."
A 26-to 30-bp region of the GM-CSF promoter, which contains the CATT(A/T) repeated sequences, has been shown to function as a mitogen responsive enhancer in T c e l l~'~~' ' and to allow mitogen-inducible transcription in vitro." However, we demonstrate that a 19-bp region containing these sequences (from bp -52 to -34, identified by our earlier DNase I footprinting studies) has strong constitutive enhancer activity in both T cell and non-T-cell lines, demonstrating that regulatory sequences outside of this region are also critical for controlling physiologic expression of GM-CSF. We show that the 12 bp CATTAATCAT'TT sequence, which has been reported to represent an AP-I binding site,'".'x is insufficient for constitutive enhancer activity in T cells and demonstrate that a TTCCT sequence located at the 3' end of the 19-bp region (which matches the consensus binding sequence for several members of the ets family of transcription factors) is required for full enhancer Constitutively expression of GM-CSF has been observed in erythroleukemia cells that constitutively express the ets protein Fli-1 (due to insertional activation by the Friend spleen focus-forming virus SFFV).*' Our results demonstrate that the ets-1 protein can bind to this 19-bp region of the GM-CSF promoter and can upregulate GM-CSF promoter function in T cells.
~~ MATERIALS AND METHODS
Tissue culture and electroporations. Cell lines were maintained in Iscove's modified Dulbecco's medium supplemented with either 10% bovine serum (MLA 144) or 10% fetal bovine serum (GCT, HeLa and S-LB-1) and penicillin, streptomycin, and 1% glutamine. All cells were fed the day before electroporation. MLA 144 T cells were electroporated using a BioRad Gene F'ulser at 250 V and 960 pF. Five or 25 micrograms of plasmid DNA was introduced into 5 x 10' cells according to previously published techniques." For studies of mitogen-responsiveness, MLA 144 cells were either stimulated with phytohemagglutinin (PHA) 1 % and 12-0-tetradecoyl phorbol myristate acetate (TPA) 20 ng/mL following the transfection, or maintained unstimulated for 16 to 20 hours. GCT and HeLa cells were efficiently transfected using a CaC12 precipitation procedurez4 and incubated at 37°C overnight. All cells were then harvested for CAT activity using standard technique^.^^ A total of 25 pg of plasmid DNA was also introduced into 5 X lo6 cells by electroporation for the cotransfection experiments; 12.5 pg of a target GM-CSF CAT reporter plasmid was cotransfected with either 12.5 pg of an expression vector construct BC1226 containing the human ets-1 cDNA, elf-1 cDNA or vector alone. Eighteen to 24 hours later the cells were harvested and CAT activity determined. (The human ets-1 and elf-1 cDNAs were kindly provided by C. Thompson [University of Chicago, Chicago, E] and cloned into the Hind 111 site of the BC12 vector).
The oligonucleotides used for creating the GM-CSF-Tk promoter-CAT reporter gene plasmids are shown in Fig 1. The pTE2 plasmid contains a multiple cloning site just 5' of the herpes simplex virus thymidine kinase (Tk) promoter. Complementary single stranded oligonucleotides were synthesized with BamHI ends, annealed, kinased, and ligated into the Bgl I1 site in the multiple cloning site of the pTE2 plasmid. The orientation of the oligonucleotides and the number of copies were confirmed using a dideoxy DNA sequencing method (Sequenase 11; US Biochemical, Cleveland, OH). Preparation of the -53 plasmid, which contains the -53 to +37 region of the GM-CSF gene upstream of the CAT gene, has been previously reported." Multiple plasmid preparations of each construct were tested in each cell type to eliminate variability due to differences in plasmid preparations.
Nuclear extracts were prepared from unstimulated and PHA/TPA stimulated MLA 144 cells and from PHA stimulated primary human T cells isolated from peripheral blood of normal volunteer donors,26
Nuclear extracts and electrophoretic mobility shifi assays. using the modified Dignam method?' In vitro translated ets-1 and elf-1 were prepared using an ets-1 or elf-1 cDNA in the CMV cDNA I neo vector (provided by C. Thompson) linearized at the Nsil I and Xba I restriction sites, respectively. In vitro transcription and translation (using rabbit reticulocytes) was performed according to the manufacturer's instructions (Promega, Madison, WI). One strand of the synthetic oligonucleotides containing GM-CSF promoter sequences (shown in Fig 1) was labeled using polynucleotide kinase and '*P -?-ATP, and then annealed to its complementary oligonucleotide. Next, 2.0 X lo5 cpm of probe was incubated with either 2 or 4 pg of nuclear extract or 3 to 6 pL of in vitro transcribed and translated recombinant protein for 30 minutes at room temperature in 30 pL of buffer containing 2 pg poly dl:dC, 20 mmol/L HEPES pH 7.9, 10% glycerol, 150 mmol/L NaCI, 20 mmol/L MgClz, 0.5 mmol/L EDTA and 1 mmol/L DIT, in the presence or absence of unlabeled competitor oligonucleotides. The IL-3 promoter oligonucleotide, used as cold competitor, contains the sequence 5' CTC-
(which extends from bp -312 to -273 relative to the IL-3 cap site).
[The AP-1 site (-302 to -296) and the ets binding site (--285 to -281)28 are indicated in bold]. Following incubation, the samples were loaded onto a 5% polyacrylamide gel and run in 0.5X TBE at room temperature. Gels were dried and exposed to XAR Kodak film (Eastman Kodak, Rochester, NY) ovemight, using an enhancing screen at -70°C.
RESULTS
GM-CSF sequences from bp -57 to -35 have enhancer activity in multiple cell types. A 23-bp region of the GM-CSF gene, containing the sequence TGGTCACCAnA-ATCAIITTCCTC, was previously shown to bind nuclear proteins present constitutively in MLA 144 T cells in DNase I footprinting experiments." To evaluate the regulatory activity of these sequences a 46-bp oligonucleotide containing two copies of this 23-bp sequence was synthesized and subcloned upstream of the Tk promoter for the initial experiments. As shown in Fig 2A, these sequences demonstrated strong constitutive enhancer activity in MLA 144 cells in either the forward or reverse orientation, generating a 100 to 300-fold greater CAT activity than the original pTE2 plasmid. The CAT activity generated by these plasmids in mitogen stimulated T cells was also 300-to 400-fold higher than the pTE2 plasmid. Multiple copies of the GM-CSF oligonucleotide generated similar levels of CAT activity to that generated by a single 46-bp oligonucleotide.
The CAT activity generated by 25 pg of these reporter plasmids in resting and mitogen stimulated cells was extremely high, so to assess the mitogen inducibility of these constructs, we transfected only 5 pg of plasmid into 5 X lo6 cells, which generated less CAT activity in unstimulated MLA 144 cells (ranging from 4% to 20% acetylation, depending on the construct) (data not shown). The construct containing a single copy of the 46-bp wild type oligonucleotide demonstrated 12.0-fold or 4.6-fold mitogen inducibility (see numbers in parentheses in Fig 2A) , and a construct containing multiple copies of this oligonucleotide was also mitogen inducible (10.8-fold). The original reporter plasmid, pTE2, was not mitogen inducible at either concentration of DNA.
To evaluate whether the repeated C A ' I T ( m ) sequences were required for the enhancer activity, a mutant oligonucle- 36.5
3.3
otide that contained multiple nucleotide substitutions in both of the CATT(AjT) repeats was tested (bottom of Fig 2A) . These constructs had no mitogen inducible CAT activity, regardless of whether the mutant oligonucleotide was in the forward or reverse orientation, or in multiple copies. The basal CAT activity of these constructs was greater than that of the pTE2 construct, but this phenomena has been observed in T cells on the introduction of a variety of mutated sequences into this vector. 29 We also examined the constitutive promoter activity of these constructs in HeLa cells and GCT cells, which are two nonhematopoietic cell lines. GCT cells have been shown to constitutively express GM-CSF,30 whereas HeLa cells do not (data not shown). Interestingly, the wild type (23-bp X 2) GM-CSF sequences generated -150-fold greater CAT activity than the enhancerless pTE2 plasmid in HeLa cells, and sixfold to eightfold greater activity in GCT cells (Fig 2B) . This activity was dependent on the presence of the CATT(A/ T) repeats; the activity of the constructs containing the mutant oligonucleotide was the same as the enhancerless pTE2 plasmid in these cell lines.
Ident$cation of minimal sequences required for enhancer activity. A smaller footprint, 19-bp in length and extending from bp -52 to -34, was previously observed when mitogen stimulated, rather than unstimulated, MLA 144 nuclear extracts were used for DNase I footprinting experiments." Based on this finding, we examined whether the GM-CSF The range of CAT activity using 25 p g of these plasmids was pTE2 (0.2% to 0.3% unrtim, 0.2% to 0.2% stiml; wild type 1 forwerd copy 19.2% to 38.5% unstim, 74.6% to 88.8% dim), two forward copies (28.5% to 69.3% undm, 74.3%to 90.1% stim); mutant one forward copy (1.0% to 1.8% unstim, 0.6% to 1.3% stiml. IBI Mean percent acetytdon generated in undmulatad nonhamatopoMk cell lines by 25 p g of wild type or mutant constructs (N = 2).
sequences in this smaller region were sufficient for enhancer function. Two or four copies of the 19-bp sequence TCA-CCATTAATCATCCT contained both constitutive and mitogen-inducible enhancer activity in MLA 144 cells, that was similar to the 23-bp GM-CSF sequence (data not shown). Because many recognition sequences for DNA binding proteins consist of palindromes or repeated sequences, we also examined whether the 12-bp region, CATTAATCA-TIT, would contain sufficient sequence information to serve as an enhancer element. Although these sequences have been reported to bind AP-1 ,I6." pTE2 constructs containing from one to six copies of the 12-bp GM-CSF sequences had no significant basal or mitogen inducible enhancer activity (data not shown).
These results suggested that the sequences flanking the CATT(A/T) repeats were critical for enhancer function, so we examined the enhancer activity of additional 19-bp oligonucleotides (diagrammed in Fig 1) that contain three bp substitutions at either the 3' end (mutant #3, disrupting the TTCCT sequence that represents a potential ets-binding site) or near the 5' end (mutant #2, disrupting the first CATT(A/T repeat). The activity of constructs containing two copies of a mutant oligonucleotide was compared with constructs containing two copies of the wild type sequence (see Fig 3) . In this set of experiments, the activity of the wild type 19-bp oligonucleotide was 40 to 110-fold higher than the pTE2 plasmid. A 20-fold lower basal activity, and a >30-fold decrease in mitogen responsive enhancer activity, was seen when the potential ets recognition sequences were disrupted (Fig 3, mutant #3 ). The activity of mutant #2 was sixfold to sevenfold higher than mutant #3, but it had only 30% of the wild type activity in unstimulated T cells, and <20% of the wild type activity in stimulated T cells. Mutant constructs #1 and #3 gave slightly higher basal activity than the enhancerless pTE2 plasmid.
To examine whether members of the ets family could transactivate the GM-CSF promoter, cotransfection experiments were performed introducing the human ets-1 cDNA expression vector and the -53 GM-CSF promoter CAT construct into resting MLA 1 4 4 cells. The -53 GM-CSF promoter CAT construct was transactivated 5.2-fold by the introduction of ets-1 (Fig 4) but was not transactivated by elf-1 (data not shown). Because elf-1 has not been shown to transactivate any of the promoter elements that it binds to in vitro, no positive control could be used for these experiments, however, this elf-1 cDNA was used successfully for in vitro transcription experiments (see below).
To evaluate the effects of ets proteins on the GM-CSF promoter, we examined the ability of ets-1 to transactivate the wild type or mutant 19-bp GM-CSF sequences, using the Tk promoter CAT constructs (Fig 4) . The 19-bp wild type GM-CSF enhancer Tk CAT plasmid was transactivated 7.7-fold by the introduction of ets-1. Mutations in the TTCCT region (mutant #3) completely abolished ets-responsiveness, whereas mutation in the 5' CAl'T(A/T) repeat (mutant #2) only slightly diminished responsiveness to ets-1 .
Characterization of DNA-protein interactions in the GM-CSF enhancer element. To characterize the binding of Tcell nuclear proteins to the GM-CSF sequences extending from bp -52 to -34, we performed electrophoretic mobility
Ets cotransfection experiments.
shift assays (EMSAs) using MLA 144 T cell nuclear extracts and radiolabeled GM-CSF wild type or mutant 19-bp oligonucleotide probes. Two major specific DNA-protein complexes were observed ( Fig 5A) ; both gel shifted bands were completely eliminated by a 100-molar excess of cold 19 To identify the proteins present in T-cell nuclear extracts that recognize the 19-bp GM-CSF sequences, we performed supershift experiments using an anti-ets-1 polyclonal antiserum (kindly provided by T. Papas, Medical University of South Carolina, Charleston) and an anti-elf-1 polyclonal antiserum (kindly provided by J. Leiden, University of Chicago, Chicago, IL) (see Fig 5B) . The retarded complex generated by in vitro translated elf-I is the same as the lower (ets) band (indicated by the arrow) generated by MLA 144 or primary human T-cell nuclear extracts (Fig 5B, compare lane 4 with lanes 6 and 7) . The additional band seen in lane 4 is also seen in lanes 1 and 5, and represents binding of proteins contained in the reticulocyte lysate. Addition of anti-elf-I antiserum to either MLA 144 T cell nuclear extracts, or primary human T cell nuclear extracts, plus the 19-bp GM-CSF wild type probe generates a slower, supershifted band (indicated by the asterisk in lanes 2 and 3 of Fig 5B) . The position of this supershifted band is the same as that generated by in vitro translated elf-I plus antielf-I antiserum (which is only weakly seen on this exposure, in lane 5).
Similar experiments using the anti-ets-1 antiserum showed no supershift using MLA 144 T cell nuclear extract and only a slight decrease in the intensity of the lower gel shift band using PHA stimulated primary T cell nuclear extract (data not shown). This antiserum generated only a weak supershift using an oligonucleotide containing the ets-1 bind- Given the ability of ets-1 to transactivate the GM-CSF promoter in MLA 144 T cells, we performed EMSAs to examine the ability of ets-1 and elf-1 to recognize sequences in the 19-bp wild type GM-CSF oligonucleotide (using in vitro transcribed and translated [IVT] ets-1 and elf-1, and either wild type or mutant GM-CSF oligonucleotides) ( Fig  6A, B, and C) . A single band was seen using the wild type GM-CSF oligonucleotide and IVT ets-1 (Fig 6A, lane 2) , whereas two bands were seen using IVT elf-1 (lane 3). The reason why two bands are generated by elf-1 is unknown, although this is also seen with the CD4 enhancer3* and the IL-2 enhancer.33 The specific binding of ets-1 is shown in lanes 1 to 4, whereas lanes 5 to 8 demonstrate the specific binding of elf-I. A 100-fold excess of unlabeled wild type oligonucleotide competed completely for binding (lanes 2 and 6), whereas neither excess mutant #1 oligonucleotide (lanes 3 and 7), nor mutant #3 oligonucleotide (which lacks the ets consensus binding sequence) (lanes 4 and 8) competed for protein binding. The proteins in the rabbit reticulocyte lysate used to make both IVT ets-1 and elf-1 do not bind to the 19-bp oligonucleotide (lane 9).
Incubation of IVT ets-1 and elf-1 with the mutant #2 oligonucleotide generated the same pattern of protein binding as the wild type oligonucleotide; a single band was seen using IVT ets-1 (Fig 6B, lane l) , and two bands were seen using IVT elf-I (lane 3). These bands represent specific binding, because no bands were seen using the rabbit reticulocytes lysate (r.r. lysate) alone (lane 5) and all bands were eliminated by a 100-fold excess of cold self-competitor (lanes 2 and 4) .
Neither ets-1 nor elf-1 binds to the mutant #3 or mutant #4 oligonucleotide. The r. r. lysate itself generated a single specific band using the mutant #4 oligonucleotide as probe (Fig 6C) , but no additional bands were generated by either IVT elf-1 or ets-1 protein. The identical pattern was seen using the mutant #3 oligonucleotide as probe (data not shown).
Detection of DNA-protein interactions using GM-CSF mutant oligonucleotides. We examined the binding of Tcell nuclear proteins to several 19-bp mutant oligonucleotides using EMSAs, to determine whether the CATT-1 and CATT-2 elements bind similar or distinct proteins and to define the sequence requirements for the binding of ets.
The mutant #3 oligonucleotide, which lacks the ets binding sequence but contains sequences that could bind YY1 or CATT(A/T) binding protein(s), generated two specific gel shift bands (indicated by the arrows in Fig 7) . A 100-fold excess of mutant #1 oligonucleotide (which lacks the CATT(A/T) motifs) does not compete, where the mutant #2 oligonucleotide, which contains the CATT-1 element in common with mutant #3 but lacks the CATT-2 element (which is thought to be the YY1 binding sequence'') competes as effectively for binding as the mutant #3 oligonucleotide itself. These results demonstrate that the CA'IT(A/T) binding protein(s) can bind DNA in the absence of the ets binding site and suggest that similar proteins can recognize the CATT-2 and CATT-1 motifs. Using the mutant #2 oligonucleotide as radiolabeled probe and various wild type and mutant competitors in EMSAs provided further evidence that the upper band represents binding of the CATT(A/T) repeat proteins and the lower band the binding of ets family members (data not shown). The CA'IT-2 sequences (and, therefore, the YY1 binding sequences) were not required for ets binding.
DISCUSSION
Lymphokines such as GM-CSF, IL-2, IL-3, or IL-4 are expressed by T cells following an activation process,' and detailed studies of the promoters for these genes have identified negative regulatory regions upstream of the mRNA initiation site for each of them.'0,26,34-37 3 ' AT-rich sequences at the 3' end of lymphokine "As (the mRNA destabilizing sequences3*) likely also prevent their constitutive expression, as do regulatory sequences located several kb upstream or downstream of lymphokine transcriptional initiation sites. 39 The 626-bp of GM-CSF 5' flanking sequences have mitogeninducible, but not basal promoter activity in T cells, whereas constructs containing only 53-bp of upstream sequences have strong constitutive activity in T cells," endothelial cells,35 fibroblasts,13 and several myeloid leukemia cell lines." This suggests that upstream sequences inhibit GM-CSF expression in the basal state and demonstrates that sequences 3' of bp -53 contain strong transcriptional regulatory activity.
In contrast to others, who have used larger regions of GM-CSF promoter sequences to test enhancer function and identified only mitogen-inducible enhancer activity, we demonstrate that the 19-bp GM-CSF sequences extending from bp -47 to -29 (TCACCATTAATCATTTCCT), can act as a strong constitutive enhancer in T cells and in cell lines that do not express GM-CSF. These 19 nucleotides are likely responsible for the strong constitutive promoter activity of the -53 construct.
Electrophoretic mobility shift assays have shown that proteins capable of recognizing these sequences are ubiquitously expressed,"' which given the limited cellular sources of GM-CSF, also suggests that cell-specific negative acting factors are critical to the appropriate regulation of GM-CSF expression. Some of these sequences may be located immediately 5' of this 19-bp region (and possibly overlapping this reg i~n ) . '~, '~ The YY1 protein has been shown to negatively regulate GM-CSF promoter function and bind to sequences upstream of the CATT(A/T) repeats, partially overlapping the CATT-2 repeat.l7 Other proteins also have inhibitory effects on the promoter activity of these sequence^'^.'^,^' and may also contribute to the lack of constitutive enhancer activity of a larger region of the GM-CSF pr~moter.'~ The sequence requirements for enhancer function are slightly different than those required for GM-CSF promoter activity. Previous studies have demonstrated that the CATT- 1 and 5) or a 500-fold excess of either unlabeled wild type oligonucleotide (lanes 2 and 61, mutant #1 (lanes 3 and 7) . or mutant #3 oligonucleotide (lanes 4  and 8) . The arrows indicate the specific bands generated by the binding of IW Identical sequences in the HTLV-I LTR have been shown to bind ets-l and be transactivated by the introduction of an ets-l expression pla~mid.4~ Although the introduction of elf-1 by cotransfection did not activate the GM-CSF sequences, cotransfection of elf-I with reporter gene plasmids containing elf-1 binding sequences from several different promoters does not change their reporter gene activity. Elf-I levels do not appear to vary following T-cell activation," but phosphorylation of Rb has been shown to dissociate elf-I from Rb;' which may regulate its DNA binding activity.
Cooperativity between members of the ets family and AP-1, NF-EMS, serum response factor, and core binding factor have been demonstrated.4X-s' Our studies demonstrate that cooperativity between members of the ets family and the CATT(A/T) binding factors is required for the function of the GM-CSF 19-bp enhancer element, although independent in vitro binding of CATT(A/T) binding proteins and ets proteins to DNA can occur. Binding of AP-I to sequences within this 19-bp region has been recently reported,".Ix but our EMSA studies and those of Ye et all7 demonstrate binding of other nuclear proteins to these GM-CSF sequences. Our EMSA results also suggest that similar proteins recognize each CATT(A/T) repeat.
The inability of the IL-3 oligonucleotide, which contains a consensus AP-I site (and an elf-I binding site), to compete for the uppermost band argues against these proteins being predominantly or exclusively AP-I, as does the ability of the mutant #4 oligonucleotide, (which lacks sequences required for AP-I binding) to efficiently compete away this upper gel shift complex. Our data also argue against a priFor personal use only. on August 30, 2017. by guest www.bloodjournal.org From mary regulatory role for AP-1 binding proteins in controlling the activity of this region of the GM-CSF promoter. The 12-bp GM-CSF oligonucleotide, which contains the putative AP-I binding sequence, is not sufficient to confer mitogenresponsiveness to the Tk promoter in T cells, in contrast to a classic TPA response element (TRE)52 (and our data not shown). Also, prior experiments performed by us and others, showed that the introduction of mutations into the CATT-2 motif, that leave the ets binding site and the putative AP-1 site in the native GM-CSF promoter intact, eliminates GM-CSF promoter activity.". 42 It has been proposed that NFAT (nuclear factor-activated T cells) can recognize GM-CSF sequences in this region, based on the ability of an IL-2 NFAT oligonucleotide to compete for binding to the GM-CSF sequences.'* However, an anti-NFATp antibody, kindly provided by Dr A. Rao (Dana-Farber Cancer Institute, Boston, MA), produces a clear supershift with the IL-2 NFAT oligonucleotide, but minimal, if any, supershift using the GM-CSF 19-bp oligonucleotide and 2 to 4 pg of MLA 144 T cell nuclear extract (data not shown). Thus, NFATp does not appear to be a major component of the DNA binding activity described in this study.
The differences between the in vitro DNA-protein interactions involving these GM-CSF sequences and their functional activity in transcription assays suggests that a complex interplay of regulatory factors controls the expression of GM-CSF. Sequences located just upstream of this enhancer element and sequences located several kb upstream of the GM-CSF gene39 have been shown to interact with this 19-bp region of the GM-CSF promoter. A link between the constitutive expression of GM-CSF (and IL-3) and the constitutive expression of the Hi-1 ets protein in Friend SFFVinduced erythroleukemia was suggested by Shimada et a1." We demonstrate that ets family members (le, ets-I) can transactivate the GM-CSF promoter.
